Eye health company Bausch + Lomb Corp. announced June 1 that it’s “reshaping” its executive team, including elevating all business unit leaders.
The changes include:
“With these changes to the executive management team, our leaders will be closer to customers and patients, which will set the stage for accelerated growth and propel Bausch + Lomb toward a highly competitive, efficient and effective future,” Saunders said in a statement.
Saunders also thanked Gordon and Yu for their contributions to the company.
Bausch + Lomb – which is headquartered in Ontario with corporate offices in Bridgewater – has undergone several major changes since its launch as a publicly traded company in May 2022. Saunders returned to the company as chairman and CEO in March – he previously served as chief executive officer from 2010 to 2013 –after Joseph Papa announced in July 2022 that he would step down.
In April, Christina Ackermann left her role as executive vice president, general counsel and president, Ophthalmic Pharmaceuticals. Bob Bailey was then named as executive vice president and chief legal officer and Andrew Stewart as president of ophthalmic pharmaceuticals.